Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 55

Results For "SMA"

1167 News Found

Jiangsu Alphamab, 3D Medicines and Glenmark sign license agreement for Envafolimab
News | January 29, 2024

Jiangsu Alphamab, 3D Medicines and Glenmark sign license agreement for Envafolimab

Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America


ImmunoBrain Checkpoint appoints Dr. Sanjay Keswani as CEO
People | January 24, 2024

ImmunoBrain Checkpoint appoints Dr. Sanjay Keswani as CEO

He is a former Neurology faculty member at The Johns Hopkins Hospital and an elected Fellow of the Royal College of Physicians, United Kingdom


European Commission grants ODD to NS-229 for treatment of Eosinophilic Granulomatosis
Clinical Trials | January 23, 2024

European Commission grants ODD to NS-229 for treatment of Eosinophilic Granulomatosis

The orphan drug designation by the EC is issued for drugs which are intended to treat diseases that affect fewer than five in 10,000 people in the European Union


INVpack presents microdosing precision in pharma and nutritional packaging for India
News | January 16, 2024

INVpack presents microdosing precision in pharma and nutritional packaging for India

Microdosing has emerged as a key trend in the pharmaceutical and nutritional markets


Apollo Hospital Seshadripuram partners with LifeSigns
Digitisation | January 16, 2024

Apollo Hospital Seshadripuram partners with LifeSigns

Inducts advanced AI-Powered 24x7 remote patient monitoring system


Aarti Pharmalabs sets up R&D Centre in Navi Mumbai
News | January 11, 2024

Aarti Pharmalabs sets up R&D Centre in Navi Mumbai

The R&D centre is mainly dedicated to the Process R&D of New Chemical Entities (NCE) development projects


Merck to acquire Harpoon Therapeutics for US$ 680 million
News | January 10, 2024

Merck to acquire Harpoon Therapeutics for US$ 680 million

Acquisition includes HPN328, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager being evaluated in certain patients with small cell lung cancer and neuroendocrine tumors


Menarini Group and Insilico Medicine ink agreement for Novel KAT6 inhibitor for treatment of breast cancer
News | January 07, 2024

Menarini Group and Insilico Medicine ink agreement for Novel KAT6 inhibitor for treatment of breast cancer

This agreement includes upfront and milestone payments with a combined potential value of over $500m and sales royalties.


Servier and Base4 partner to advance neuroscience drug development
Clinical Trials | January 06, 2024

Servier and Base4 partner to advance neuroscience drug development

Base4's drug discovery platform allows its collaborators to evaluate billions of novel small molecules to identify and progress RNA-modulators for important diseases